Anti-cancer drug is well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications.
Amyloidosis
Amyloidosis is a rare disease due to build up of abnormal proteins called amyloid in different tissues and organs of the body causing damage to the structure and affecting their normal functioning.
Amyloidosis is a rare disease due to build up of abnormal proteins called amyloid in different tissues and organs of the body causing damage to the structure and affecting their normal functioning.
‘AL amyloidosis is a disease related to bone marrow cancer; multiple myeloma. AL amyloidosis is considered life threatening due to amyloid fibril deposition in various organs of the body leading to organ failure.’
According to the researchers, daratumumab infusion in myeloma patients can cause infusion related reactions in almost half of the cases so it was important to study this drug with appropriate premedications in AL amyloidosis. Twenty-two patients with previously treated AL amyloidosis were enrolled in a prospective study. The majority of the patients had received high-dose melphalan and stem cell transplantation (HDM/SCT) and/or treatment with a proteasome inhibitor. The researchers found daratumumab to be safe, tolerable and successful in treating these patients. In addition, due to its favorable toxicity profile, they believe daratumumab is an attractive treatment option for patients with advanced cardiac involvement with AL amyloidosis.
"Only one dose of daratumumab can decrease the amyloidogenic precursor immunoglobulin light chain protein rapidly and can lead to reversal of organ dysfunction in patients with AL amyloidosis," explained corresponding author and principal investigator of this clinical trial Vaishali Sanchorawala, MD, director of the Boston University/Boston Medical Center Amyloidosis Center.
New Drug Offers Hope for Patients with Bone Marrow Cancer
New study offers hope for patients with a serious type of bone marrow cancer as a new therapeutic drug has revealed improved outcomes and survival rates.
New study offers hope for patients with a serious type of bone marrow cancer as a new therapeutic drug has revealed improved outcomes and survival rates.
Source-Eurekalert
Pattern of Hospital Visits may Offer a Clue to Spot People at Risk of Myeloma
Condition that can progress to myeloma could be recognized in patients by their unusually frequent hospital visits, according to a new study.
Condition that can progress to myeloma could be recognized in patients by their unusually frequent hospital visits, according to a new study.
BUSM Researchers Part of Multi-center Study on Cardiac Amyloidosis
A multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) has been conducted in collaboration with researchers at BUSM
A multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) has been conducted in collaboration with researchers at BUSM
